$31.095
+1.894 (+6.09%)Zum Schluss
Kursprognosen
In der App öffnen, um Prognosen mit längerem Horizont freizuschalten.
Soll ich IRulya Therapeutics Inc.-Aktien kaufen?
IRulya Therapeutics Inc is not a good buy right now due to its significant financial losses and weak performance indicators. The stock is currently priced at 31.09, but it has a forward P/E of 0 and a negative EPS estimate of -0.8300 for the upcoming earnings report. Additionally, the company has reported a net income loss of -39,458,000 for Q4 2025, indicating ongoing financial struggles. The main risk is its declining current ratio, which has fallen to 0.53, suggesting potential liquidity issues.
IRLA schloss am Friday bei $31.09, nachdem der Kurs +6.09% gestiegen ist
IRulya Therapeutics Inc. (IRLA) last closed at $31.0949993, gaining +6.09%. These facts feed the 1-day and 1-week IRLA price prediction above.
Prognose-Treiber
Die Prognose-Treiber von IRulya Therapeutics Inc. (IRLA) kombinieren ähnliche Chartmuster, Saisonalität und gleitende Durchschnitte.
Seasonality
Bearish
Saisonalitätsanalyse für IRLA
Ähnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.